Abstract:Background Biological disease modifying antirheumatic drugs (bDMARDs) have been increasingly prescribed for RA in mainland China. Large scale epidemiological studies are needed to understand the treatment patterns and experience of bDMARD therapy in China. Objectives To characterize bDMARD therapy in Chinese RA patients in routine clinical practice. Methods Fifteen Chinese hospitals participated in this multi-center cross-sectional observational study. Consenting patients aged ≥18 years diagnosed with RA and receiving marketed bDMARDs were included. Results In total, 802 patients (81.3% women) met the inclusion criteria. The mean age (SD) was 49.0 (13.9) years. Analysis of available data of dosage and treatment duration of bDMARDs for all patients revealed that 66.6% patients were receiving ETN at a mean (SD) weekly dose of 38.2 (15.6) mg for 25.5 (47.0) weeks. The second most common bDMARD was tocilizumab administered to 17.0% patients at a mean weekly dose of 94.5 (21.9) mg for 4.7 (7.5) weeks. Only 7.5% and 6.6% patients were receiving adalimumab and infliximab, respectively. Using DAS28 score as the evaluation index, 32.8%, 42.2%, 12.4%, and 12.6% patients showed high, medium, low disease activity, and disease remission, respectively. Compared with patients (62.7%) receiving bDMARDs for <3 months, whose DAS28 score was 4.6 (1.5), those receiving bDMARDs for ≥3 months exhibited significantly lower DAS28 scores (P<0.0001). In particular, patients (14.6%) receiving bDMARDs for ≥12 months exhibited DAS28 scores of 3.2 (1.4). In total, 89.5% patients were receiving a combination of bDMARDs and cDMARDs whereas 10.5% patients were receiving bDMARD monotherapy. Among the 84 patients receiving bDMARD monotherapy, 75.0%, 10.7%, 9.5%, and 4.8% were receiving etanercept (ETN), infliximab, tocilizumab, and adalimumab respectively; for ETN, 8.3% and 66.7% patients were using original ETN (Enbrel®) and ETN biosimilar (Yi Sai Pu®), respectively. Patients receiving concomitant therapy exhibited significantly lower DAS28 than patients receiving bDMARD monotherapy (4.3 vs. 4.8, P=0.011). Reasons for discontinuing or switching bDMARDs varied. For patients (n=58) who had received the same bDMARDs previously, the main reasons for discontinuing the bDMARDs were improvement of disease condition (31%), financial burden (24.1%), and adverse reactions (13.8%). For patients (n=93) switching to different bDMARDs, the main reasons were unsatisfactory efficacy of the previous bDMARDs (58.1%), adverse reactions (14.0%), improvement of disease condition (10.8%), and financial burden (10.8%). Conclusions This is the first large scale multi-center study to characterize bDMARD therapy in China. Patients receiving bDMARDs ≥3 months showed significantly lower DAS28 scores than patients receiving bDMARDs <3 months, although the treatment target was not achieved within 12 months in routine practice. Currently, ETN and tocilizumab are the most commonly used bDMARDs in China, and the proportion of patients receiving bDMARD monotherapy is lower than that in European countries. These results suggest that bDMARD therapy in China can be improved in many aspects. Acknowledgements This study was sponsored by Shanghai Roche Pharmaceuticals Limited Disclosure of Interest None declared

Investigation of current situation of 694 Patients with Rheumatoid Arthritis in China

Remission Assessment of Rheumatoid Arthritis in Daily Practice in China: a Cross-Sectional Observational Study.

Satisfaction of Patients and Physicians with Treatments for Rheumatoid Arthritis: A Population-Based Survey in China.

The investigation of hydroxychloroquine usage in patients with rheumatoid arthritis in China

Cross-sectional study of the clinic behavior and therapeutic status of rheumatoid arthritis patients

Disability and Health-Related Quality of Life in Chinese Patients with Rheumatoid Arthritis: A Cross-Sectional Study.

Investigating the Safety and Compliance of Using Csdmards in Rheumatoid Arthritis Treatment Through Face-to-face Interviews: a Cross-Sectional Study in China.

A cross-sectional survey of glucocorticoids application in patients with rheumatoid arthritis

[The standardized diagnosis and treatment of rheumatoid arthritis].

Nurse-supported care versus rheumatologist-led care in patients with rheumatoid arthritis at high disease activity: A retrospective study of two Chinese centers

Analysis of TCM Syndromes and Clinical Manifestations of Rheumatoid Arthritis Patients Based on Real-world Study

AB1194 Treatment of Rheumatoid Arthritis with Biological Dmards in China: A Multi-Center Cross-Sectional Study

AB0387 SATISFACTION OF PATIENTS AND PHYSICIANS WITH TREATMENTS FOR RHEUMATOID ARTHRITIS: A NATIONWIDE SURVEY IN CHINA

System Assessment of Active Stage of Rheumatoid arthritis Treated by Qingrechushi Traditional Chinese Medicine

Chinese registry of rheumatoid arthritis (CREDIT) V: sex impacts rheumatoid arthritis in Chinese patients

A Retrospective Analysis of 1444 Cases of Rheumatoid Arthritis Patients

Comprehensive review of patients with hypercoagulable state in rheumatoid arthritis and strategies to reduce readmission rates: A retrospective cohort study based on protective exploration of traditional Chinese medicine

Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China

Investigation and Analysis of Life Quality of Patients with Rheumatoid Arthritis

The investigation of work disability of rheumatoid arthritis patients

Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey